Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray.

Martinez-Morilla S, McGuire J, Gaule P, Moore L, Acs B, Cougot D, Gown AM, Yaziji H, Wang WL, Cartun RW, Hornick JL, Sholl LM, Qiu J, Mino-Kenudson M, Yi ES, Beasley MB, Merrick DT, Ambaye AB, Zhang ZJ, Walker J, Rimm DL.

Lab Invest. 2019 Aug 13. doi: 10.1038/s41374-019-0295-9. [Epub ahead of print]

PMID:
31409885
2.

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.

Gaule P, Mukherjee N, Corkery B, Eustace AJ, Gately K, Roche S, O'Connor R, O'Byrne KJ, Walsh N, Duffy MJ, Crown J, O'Donovan N.

Cancers (Basel). 2019 Apr 17;11(4). pii: E548. doi: 10.3390/cancers11040548.

3.

A Field Experiment on Search Costs and the Formation of Scientific Collaborations.

Boudreau KJ, Brady T, Ganguli I, Gaule P, Guinan E, Hollenberg A, Lakhani KR.

Rev Econ Stat. 2017 Oct;99(4):565-576. doi: 10.1162/rest_a_00676. Epub 2017 Oct 3.

4.

B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.

Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL.

Clin Cancer Res. 2017 Sep 1;23(17):5202-5209. doi: 10.1158/1078-0432.CCR-16-3107. Epub 2017 May 24.

5.

Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.

Smithy JW, Moore LM, Pelekanou V, Rehman J, Gaule P, Wong PF, Neumeister VM, Sznol M, Kluger HM, Rimm DL.

J Immunother Cancer. 2017 Mar 21;5:25. doi: 10.1186/s40425-017-0229-2. eCollection 2017.

6.

A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1.

Gaule P, Smithy JW, Toki M, Rehman J, Patell-Socha F, Cougot D, Collin P, Morrill P, Neumeister V, Rimm DL.

JAMA Oncol. 2017 Feb 1;3(2):256-259. doi: 10.1001/jamaoncol.2016.3015.

7.

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.

Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL.

Clin Cancer Res. 2017 Jan 15;23(2):370-378. doi: 10.1158/1078-0432.CCR-16-0150. Epub 2016 Jul 20.

8.

cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?

Gaule PB, Crown J, O'Donovan N, Duffy MJ.

Expert Opin Ther Targets. 2014 Sep;18(9):999-1009. doi: 10.1517/14728222.2014.938050. Epub 2014 Aug 1. Review.

PMID:
25084805
9.

BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome.

Madden SF, Clarke C, Gaule P, Aherne ST, O'Donovan N, Clynes M, Crown J, Gallagher WM.

Breast Cancer Res. 2013;15(4):R52.

10.

Access to vaccine technologies in developing countries: Brazil and India.

Milstien JB, Gaulé P, Kaddar M.

Vaccine. 2007 Nov 1;25(44):7610-9. Epub 2007 Sep 20.

PMID:
17913312

Supplemental Content

Support Center